Search Videos and More

Showing 157 - 168 of 183 results

Previous| 1... 13 | 14 | 15 ...16 |Next


Targeted Agent Shows Early Promise Against a Dangerous Infant Leukemia News

Targeted Agent Shows Early Promise Against a Dangerous Infant Leukemia

Leukemias involving reshuffling or rearrangement of the mixed lineage leukemia (MLL) gene, known as MLL-rearranged or MLL-r leukemias, account for 70 to 80 percent of acute leukemias in infants under one year old. In these blood cancers, a subset of acute myeloid and acute lymphoid leukemias (AML and ALL), the MLL gene breaks and reattaches to the wrong section of the chromosome.
Looking for Cancer’s Achilles Heel: The Pediatric Cancer Dependency Map News

Looking for Cancer’s Achilles Heel: The Pediatric Cancer Dependency Map

Thanks to developments in precision medicine, some adult cancers are now treated with designer drugs that target the genetic mutations that caused them. But most children with cancer have not reaped the same benefits. Unlike adult cancers, childhood cancers carry few genetic mutations.
Researchers Focus on How to Invigorate ‘Exhausted’ T-Cells in Immunotherapy News

Researchers Focus on How to Invigorate ‘Exhausted’ T-Cells in Immunotherapy

Despite the sometimes-dramatic success of new cancer immunotherapies like checkpoint inhibitor drugs and CAR T cells, thus far only a minority of patients have responded or gained long-lasting benefits.
mRNA Takes Center Stage in COVID-19 Vaccine and Cancer Research News

mRNA Takes Center Stage in COVID-19 Vaccine and Cancer Research

Having come to fame as the basis of the Moderna and Pfizer/BioNTech vaccines for COVID-19, messenger RNA — or mRNA — is in many ways the molecule of the moment.
Dana-Farber Cancer Institute Faculty Recognized as 2021 ASCO Leaders in Cancer Care News

Dana-Farber Cancer Institute Faculty Recognized as 2021 ASCO Leaders in Cancer Care

The American Society of Clinical Oncology (ASCO) recognized two Dana-Farber Cancer Institute researchers as winners of ASCO's Special Awards, the Society’s highest honors. The recipients of these awards have worked to transform cancer care around the world.
Study Uncovers Potent Immunotherapy Approach to Ovarian Cancer Treatment News

Study Uncovers Potent Immunotherapy Approach to Ovarian Cancer Treatment

Immune therapies declare open season on cancer, rousing immune system cells to take up an attack on tumors. But which immune cells join the hunt, which sit it out, and what happens within immune cells that causes them to go on the offensive?
Level of Chromosomal Abnormality in Non-small Cell Lung Cancer May Predict Response to Immunotherapy News

Level of Chromosomal Abnormality in Non-small Cell Lung Cancer May Predict Response to Immunotherapy

Dana-Farber researchers find patients whose tumors have low aneuploidy levels often have better outcomes following treatment with immune checkpoint inhibitors.
Pediatric Fertility Preservation Program News

Pediatric Fertility Preservation Program

At Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, we value the importance of fertility and reproductive health as it relates to long-term quality of life. As treatment for childhood cancers and blood disorders have improved, more and more survivors are entering their reproductive years and thinking about starting families of their own. The fertility preservation team will work closely with patients’ primary care team to ensure that a fertility consultation takes place as a part of the patient’s comprehensive work-up.
Expert Panel Issues Recommendations for Addressing Cancer Inequities News

Expert Panel Issues Recommendations for Addressing Cancer Inequities

New recommendations co-developed by Dana-Farber Cancer Institute call for a significant expansion of the National Cancer Institute (NCI) and NCI-designated Comprehensive Cancer Centers to understand the causes of inequities in cancer care and a commitment to building sustained community partnerships to reduce them.
In Landmark Study, an Arthritis Drug Appears to Prevent Deadly Acute Graft-versus-host Disease after Bone Marrow Transplant News

In Landmark Study, an Arthritis Drug Appears to Prevent Deadly Acute Graft-versus-host Disease after Bone Marrow Transplant

An immune-suppressing drug normally used to treat rheumatoid arthritis could make bone marrow transplant safer, report researchers at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center. In a Phase 2 multi-center trial, the drug abatacept (ORENCIA®) reduced rates of severe, acute graft-versus-host disease (GVHD) and boosted rates of survival without acute GVHD or relapse in patients with leukemia and other blood cancers.
First FDA Approval of CAR T-Cell Therapy for Multiple Myeloma Marks Milestone for Patients News

First FDA Approval of CAR T-Cell Therapy for Multiple Myeloma Marks Milestone for Patients

The Food and Drug Administration (FDA) has granted its first approval of a CAR T-cell therapy for adults with multiple myeloma, bringing welcome hope for patients eligible for the treatment, according to researchers and physicians at Dana-Farber Cancer Institute.
Study Underscores Need for Multidisciplinary Care for COVID-19 Long-Haulers News

Study Underscores Need for Multidisciplinary Care for COVID-19 Long-Haulers

Physicians across the country have analyzed the emerging scientific data about the long-term effects of COVID-19, creating an initial knowledge base about the clinical experiences of so-called “long-haulers” – patients with COVID-19 who experience prolonged symptoms and/or the emergence of new ones well after the initial viral infection has resolved. A comprehensive review published today in Nature Medicine offers an initial glimpse of the multi-organ effects of long-term COVID-19 and suggests a framework for the care of COVID-19 long-haulers through dedicated, multidisciplinary clinics.

Showing 157 - 168 of 183 results

Previous| 1... 13 | 14 | 15 ...16 |Next